Medicare Enrolled

Dr. Brittany Dashevsky, MD

Radiation Oncology · Stanford, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
300 PASTEUR DR, Stanford, CA 94305
6507234000
In practice since 2012 (13 years)
NPI: 1467719294 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dashevsky from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dashevsky? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Dashevsky

Dr. Brittany Dashevsky is a radiation oncology specialist in Stanford, CA, with 13 years of NPI registration. Based on federal Medicare data, Dr. Dashevsky performed 825 Medicare services across 821 unique beneficiaries.

Between the years covered by Open Payments, Dr. Dashevsky received a total of $1,385 from 30 pharmaceutical and/or device companies across 67 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in radiation oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Dashevsky is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 13 years in practice ▲ 825 Medicare services $1,385 industry payments

Medicare Practice Summary

Medicare Utilization ↗
825
Medicare services
Bottom 29% in CA for radiation oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
821
Unique beneficiaries
$43
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~63 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
3D screening mammography (tomosynthesis)
A screening imaging test of the breast using 3D technology to detect potential abnormalities.
238 $33 $180
Screening mammography
An X-ray of the breast used to detect breast cancer in women who have no signs or symptoms of the disease.
238 $42 $209
Digital breast tomosynthesis (3D mammogram)
A specialized imaging test that creates three-dimensional pictures of the breast tissue to help detect abnormalities.
66 $24 $170
MRI scan of both breasts
A magnetic resonance imaging test that creates detailed pictures of both breasts to help evaluate breast tissue.
61 $89 $888
Diagnostic mammography of 1 breast
An X-ray examination of one breast to evaluate specific breast symptoms or abnormalities.
43 $31 $239
Diagnostic mammography of both breasts 39 $42 $294
Limited ultrasound of 1 breast
A focused ultrasound examination of a single breast to evaluate specific areas of concern.
38 $29 $157
Complete breast ultrasound, 1 breast
A complete ultrasound examination of one breast to visualize internal structures.
30 $46 $499
Limited ultrasound of joint or extremity
A focused ultrasound exam of a specific joint or other structure in the arm or leg, excluding blood vessels.
28 $28 $136
X-ray of surgical specimen 17 $14 $56
Breast biopsy with ultrasound-guided localization device placement
This procedure involves taking a tissue sample from a breast growth and placing a marker device to locate it, guided by ultrasound imaging.
15 $134 $2,919
Breast biopsy with localization device using X-ray
A procedure to remove a sample of breast tissue for testing, using X-ray guidance to place a device that marks the location of the first growth.
12 $144 $2,946
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2022 ↗
$1,385
Total received (2018-2022)
Avg $277/year across 5 years
Top 22% in CA for radiation oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
30
Companies
67
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,385 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2022
$305
2021
$536
2020
$272
2019
$207
2018
$65

Payments by company (2022)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$44
Seagen Inc.
$28
GlaxoSmithKline, LLC.
$26
Regeneron Healthcare Solutions, Inc.
$25
MorphoSys, US Inc.
$25
Exelixis Inc.
$23
AstraZeneca Pharmaceuticals LP
$22
Incyte Corporation
$20
Novartis Pharmaceuticals Corporation
$20
BeiGene USA, Inc.
$19
Janssen Biotech, Inc.
$19
Celgene Corporation
$18
Hologic, LLC
$16
Top 3 companies account for 32.3% of 2022 payments
All-time payments by company (2018-2022) ›
Amgen Inc.
$191
Merck Sharp & Dohme Corporation
$125
Seagen Inc.
$104
Incyte Corporation
$103
AstraZeneca Pharmaceuticals LP
$83
Takeda Pharmaceuticals U.S.A., Inc.
$67
Lilly USA, LLC
$64
Janssen Biotech, Inc.
$63
GlaxoSmithKline, LLC.
$59
Exelixis Inc.
$42
BeiGene USA, Inc.
$39
Novartis Pharmaceuticals Corporation
$36
HOLOGIC INC
$36
Foundation Medicine, Inc.
$34
Gilead Sciences, Inc.
$25
Regeneron Healthcare Solutions, Inc.
$25
MorphoSys, US Inc.
$25
AbbVie, Inc.
$25
Alexion Pharmaceuticals, Inc.
$25
Rigel Pharmaceuticals, Inc.
$24
Eisai Inc.
$23
Agios Pharmaceuticals, Inc.
$23
GENZYME CORPORATION
$22
Taiho Oncology, Inc.
$19
E.R. Squibb & Sons, L.L.C.
$18
Celgene Corporation
$18
JAZZ PHARMACEUTICALS INC.
$18
Jazz Pharmaceuticals Inc.
$17
Daiichi Sankyo Inc.
$16
Hologic, LLC
$16
Top 3 companies account for 30.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AIXPLORER ULTIMATE · ALUNBRIG · BLENREP · BRUKINSA · Cabometyx · Clarity · ERLEADA · Enhertu · FOUNDATIONONE · Halaven · IMBRUVICA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUMAKRAS · LYNPARZA · MONJUVI · Neulasta · Nplate · PEMAZYRE · Pomalyst · TIBSOVO · TUKYSA · Tavalisse · Trodelvy · Ultomiris · VERZENIO · Venclexta · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a radiation oncology specialist in Stanford?
Compare radiation oncologists in the Stanford area by procedure volume, costs, and industry payment transparency.
Browse radiation oncologists nearby

Geographic Context

Radiation oncologists within 10 mi
542
Per 100K population
28.5
County median income
$159,674
Nearest hospital
STANFORD HEALTH CARE
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2022
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Dashevsky is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Dashevsky experienced with 3d screening mammography (tomosynthesis)?
Based on Medicare claims data, Dr. Dashevsky performed 238 3d screening mammography (tomosynthesis) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dashevsky receive payments from pharmaceutical companies?
Yes. Dr. Dashevsky received a total of $1,385 from 30 companies across 67 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dashevsky's costs compare to other radiation oncologists in Stanford?
Dr. Dashevsky's average Medicare payment per service is $43. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dashevsky) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →